Experimental drugs bring hope to diabetics

The rate of diabetics has been increasing substantially in America over the past decade. 28 million Americans are said to be diabetic while 7 million of them are yet undiagnosed. 57 million people of the country are pre-diabetic. The Centers for Disease Control and Prevention (CDC) has gone ahead and called the change an epidemic. Another fact to be concerned is that, The American Diabetes Association said that one in every three Americans born after the year 2000 will develop diabetes sometime in their life.

Diabetes is primarily a metabolic disorder. A person with this disorder will have high blood sugar either because his/her body does not produce enough insulin or if the produced insulin is not used efficiently by the body.

But there may yet be hope for the people. New experimental treatments that are in late testing have given hope to people around the world.  At the American Diabetes Association conference that was held in Philadelphia, diabetes specialists have been presenting data that brings optimistic news to diabetics and the drug makers.

More Drugs for Cancer in 2012

The applications at the U.S Food and Drug Administration for cancer drugs are rising with 20 submissions expected this year. The increase in the application is due to a better understanding of the molecular makeup of the disease leads to new treatments. Some techniques which are proving successful are the targeting specific gene mutations in tumors and harnessing the body’s own immune system to find and kill cancer cells.

Dr. Richard Pazdur, head of FDA’s office of oncology products said, “There are a large number of drugs being developed in oncology, there is greater understanding of some of the disease processes”. Last year 10 out of the 30 drugs approved by the FDA were for cancer treatment. Dr. Pazdur said that in terms of approval some of the drugs may take next year or longer than expected to review due to issues such as manufacturing and some may not be approved at all. This year some of the cancer drugs approved so far are Roche’s Erivedge for basal cell carcinoma, Pfizer’s Inlyta for kidney cancer, GlaxoSmithKline’s Votrient for soft tissue sarcoma and Leo Pharma’s Picato for actinic keratosis. By Friday the FDA is scheduled to decide on Roche’s application for Pertuzumab which is an antibody designed for use in 25 percent of breast cancer patients whose tumors produce a protein called HER-2 which can fuel cancer growth.

 

Switch to our mobile site